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by the production and progressive accumulation of a fibrillar
extracellular material in many ocular tissues [1]. It is now
understood to be the most common identifiable cause of open-
angle glaucoma worldwide, accounting for the majority of
cases of this disease in some countries [2]. Its incidence
increases progressively with age while its widespread
distribution, its frequency, and its potential association with
other diseases is only beginning to be realized.
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Purpose: To evaluate genetic susceptibility of lysyl oxidase-like 1 (LOXL1) gene polymorphisms to exfoliation syndrome
(XFS) and exfoliation glaucoma (XFG) in a case-control cohort of American and European patients.
Methods: DNA from a total of 620 individuals including 287 exfoliation patients and 333 healthy control subjects were
extracted by standard methods. Three single nucleotide polymorphisms (SNPs) of rs1048661 (R141L), rs3825942
(G153D), and rs2165241 were genotyped in these individuals by SNaPshot Assay. The seven coding exons of the
LOXL1 gene and their immediate flanking regions were directly sequenced in 95 affected patients. Data management and
case-control association studies were performed with SNP-STAT and PLINK programs. The obtained DNA sequences
were evaluated with the STADEN package.
Results: The 287 unrelated exfoliation cases comprised of 171 American patients (mostly of European background) and
116 patients from 12 European countries. This phenotype was further divided into patients with exfoliation only and no
glaucoma (XFO; n=95), exfoliation with glaucoma (XFG; n=133), and exfoliation unclassified (XFU; n=59). Genotypic
data were analyzed separately for XFO, XFG, XFU, and XFS (all exfoliations; n=287) and for Americans and Europeans.
The observed genotypic frequencies for each exfoliation phenotype or population were tabulated separately and tested for
deviation from the Hardy–Weinberg equilibrium (HWE) using a standard Χ2 test. There were no HWE deviations and no
significant genotypic differences between these subcategories for the three studied SNPs. For the combined exfoliation
cohort, homozygote genotypes of G/G (rs1048661), G/G (rs3825942), and T/T (rs2165241) were significantly
overrepresented. Likewise, case-control allelic association for rs1048661 (p=7.74x10−9), rs3825942 (p=3.10x10−17), and
rs2165241 (p=4.85x10−24) were highly significant. The corresponding two-locus haplotype frequencies of GG for
rs1048661-rs3825942 (p=1.47x10−27), GT for rs1048661-rs2165241 (p=1.29x10−24), and GT for rs3825942-rs2165241
(p=2.02x10−24) were highly associated with exfoliation phenotypes. The combined effect of these three SNPs revealed
that the GGT haplotype is overrepresented by 66% in exfoliation cases, and this deviation from controls is highly significant
(p=1.93x10−24). This haplotype constituted a major risk factor for development of exfoliation in both XFS and XFG. By
contrast, the GAC haplotype was significantly underrepresented (p=4.99x10−18) in exfoliation cases by 83% and may
potentially have a protective effect for this condition with an estimated attributable risk percent reduction of 457%. The
only other haplotype that was significantly different between cases and controls was TGC (p=5.82x10−9). No observation
was made for the GAT haplotype. The combined three haplotypes of GGT, GAC, and TGC were associated with 91% of
the exfoliation syndrome cases in the studied populations. Seven coding exons of LOXL1 were also sequenced in 95
affected cases. In addition to the three above-mentioned SNPs, 12 other variations were also observed in these patients
(G240G, D292D, A320A, V385V, rs2304719, IVS3+23C>T, IVS3–155G>A, IVS3–101G>A, IVS4+49G>A,
rs2304721, IVS5–121C>T, and rs2304722). None were considered a disease-causing mutation.
Conclusions: We confirmed a strong association with LOXL1 variants in our patients. For the LOXL1 gene, individual
alleles of rs1048661 (G), rs3825942 (G), and rs2165241 (T) are highly associated with XFS and XFG in American and
European populations. The GGT haplotype constitutes a major risk haplotype for exfoliation, and GAC may have a
protective role. DNA sequencing of 95 affected patients did not show any mutations in this gene. The LOXL1 SNPs are
located in the 15q24.1 band and within a genetic locus (GLC1N) that is associated with primary open-angle glaucoma
(POAG). However, the LOXL1 genetic predisposition is only limited to exfoliation with or without glaucoma and does
not include the POAG phenotype.
All anterior segment structures are involved in XFS.
Deposits of white material on the anterior lens surface are the
most consistent and important diagnostic feature. The classic
pattern consists of three distinct zones that become visible
when the pupil is fully dilated, a central disc, an intermediate
clear zone created by the iris rubbing exfoliation material from
the lens surface during its physiologic excursions, and a
granular peripheral zone [1]. Exfoliation material is often
found at the pupillary border.
Exfoliation material is a complex glycoprotein/
proteoglycan structure bearing epitopes of the basement
membrane and elastic fiber system. The characteristic fibrils,
which are composed of microfibrillar subunits surrounded by
an amorphous matrix comprising various glycoconjugates,
contain predominantly epitopes of elastic fibers such as
elastin, tropoelastin, amyloid P, vitronectin, and components
of elastic microfibrils such as fibrillin-1, microfibril-
associated glycoprotein-1, and latent transforming growth
factor beta-binding proteins (LTBP1 and LTBP2) by
immunohistochemistry [1,3].
The risk of developing glaucoma is 5–10 times more
common in eyes with XFS than in those without it. About 25%
of patients with XFS have elevated intraocular pressure (IOP),
and one-third of these have glaucoma. Patients with XFS are
twice as likely to convert from ocular hypertension to
glaucoma, and when glaucoma is present, it progresses more
rapidly [4-6].
Exfoliation syndrome leads not only to severe, chronic
open-angle glaucoma but may also lead to lens subluxation,
angle-closure, blood-aqueous barrier impairment, and serious
complications at the time of cataract extraction such as zonular
dialysis, capsular rupture, and vitreous loss. There is
increasing evidence for an etiological association of XFS with
cataract formation and with retinal vein occlusion. Deposits
of exfoliation material have been found in the heart, lung,
liver, kidney, gall bladder, and cerebral meninges by electron
microscopy [7,8].
An increasing number of associations with specific
systemic disorders, primarily related to vasculopathy, has
been reported including transient ischemic attacks [9],
hypertension, angina, myocardial infarction, stroke,
asymptomatic myocardial dysfunction [10], Alzheimer
disease [11-13], and hearing loss [14,15].
Exfoliation syndrome is seemingly inherited as an
autosomal dominant condition as evidenced by the largest
available pedigree described in Nova Scotia [16]. Although,
mitochondrial and even multifactorial modes of inheritance
have also been suggested for XFS [17], familial cosegregation
has been observed in many populations. A genome-wide
linkage study of the Finnish population has recently identified
a promising genetic locus on 18q with a multipoint LOD score
of 4.2 as well as other potential loci on 2q, 17p, and 19q
[18]. We also identified a provisional locus on the 2q36
region, but mutation screening of over 20 genes has not as yet
identified the defective molecule for XFS (unpublished data).
A recent genome-wide association study in the Icelandic
population identified multiple single nucleotide
polymorphisms (SNPs) in the lysyl oxidase-like 1 (LOXL1)
gene on 15q24.1 that are highly associated with the exfoliation
phenotype [19]. Replication studies in the Swedish population
confirmed genetic susceptibility of LOXL1 polymorphisms to
exfoliation with (XFG) or without glaucoma (XFS) [19].
However, no genetic association was observed in a group of
unrelated primary open-angle glaucoma (POAG) for either of
these two populations.
In this study, we investigated the role of LOXL1
polymorphisms in 620 American and European patients (287
exfoliation and 333 controls). Our study confirmed that the
LOXL1 polymorphisms are highly associated with both XFS
and XFG patients in the two populations studied.
METHODS
Clinical diagnosis: The diagnosis of exfoliation syndrome
was made by direct visualization on a slit-lamp examination
of the typical pattern of exfoliation material on the anterior
lens surface after pupillary dilation. Exfoliative glaucoma was
diagnosed as those showing the characteristics of a history of
intraocular pressure greater than or equal to 22 mmHg and a
presence of typical glaucomatous optic disc cupping and
visual field loss.
Patient population: The patient population was composed of
two major subgroups, Americans and Europeans (Table 1). A
total of 171 American exfoliation cases (93 XFG) were
examined and clinically diagnosed by two of the authors (R.R.
and J.L.). All but five patients in this subgroup were of
European ancestry.
The remaining 116 patients (40 XFG) were from 12
European countries, primarily Irish, Scottish, English,
Finnish, or Maltese. Their exfoliation and glaucoma
diagnoses were made by their respective ophthalmologists.
Several of them were found to have additional family
members affected with exfoliation or glaucoma in a pattern
suggesting autosomal dominant inheritance [17,20]. Many of
these family members were clinically and genetically
ascertained, and their DNA samples were collected. However,
TABLE 1. DISTRIBUTION OF EXFOLIATION PATIENTS WITH NO GLAUCOMA (XFO),
EXFOLIATION WITH GLAUCOMA (XFG), AND EXFOLIATION UNCLASSIFIED (XFU)
IN AMERICAN AND EUROPEAN PATIENTS.
Subtype American European Total
XFO 72 23 95
XFG 93 40 133
XFU 6 53 59
XFS 171 116 287
XFS represents all exfoliation groups combined.
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for this case-control association study, only one affected
member per family was used.
Of the 287 unrelated exfoliation patients included in this
study (Table 1), only 133 (93 Americans) were reported to
have exfoliation glaucoma (XFG). Further, 95 (72 Americans)
cases were reported to have only exfoliation (XFO) with no
glaucoma. The glaucoma status for the remaining 59 (six
Americans) unrelated patients was not reported, and thus,
these cases were considered as unclassified (XFU).
Altogether, 287 patients with exfoliation syndrome (XFS)
including 133 XFG were used for statistical evaluation.
Similarly, we used a group of 333 unrelated healthy
control subjects from the United States and Europe. To the
best of our knowledge, none of the control individuals who
participated in this study was related to our exfoliation
patients. All of these healthy controls were clinically screened
for the presence of exfoliation and glaucoma, and the majority
of them declared as having a European genetic background.
All the controls were between 60 and 98 years old and so they
were age- and ethnically-matched with our exfoliation group.
The inclusion of human subjects in our study was
approved by the University of Connecticut Health Center
Institutional Review Board.
SNaPshot genotyping assay: SNP genotyping was performed
by the SNaPshot Assay. Unmodified, flanking
oligonucleotide primers were synthesized and the polymerase
chain reaction (PCR) product of each targeted SNP was
generated separately by standard PCR reactions as described
below. DNA samples from 620 unrelated exfoliation cases
and controls were used for PCR amplification of three
different LOXL1 SNP markers, and their PCR products were
pooled together separately for each individual. We also
synthesized three other internal primers that would anneal to
sequences adjacent to the exact site of each SNP marker.
Subsequently, the pooled PCR products were subjected to a
second round of PCR amplification using the ABI-SNaPshot
Multiplex Kit and unlabeled internal primers. The new PCR
reaction extended by only one nucleotide base at the exact site
of the SNP and then terminated. The SNaPshot Multiplex Kit
contains four ddNTPs that are fluorescently labeled with a
different color dye. Since the length of our internally designed
primers differed by at least 10 base pairs (bp), the newly
generated fragments varied by size for various SNPs and by
color for the allelic polymorphism within each SNP.
Therefore, based on the two distinctive color and size
differences, these multiplex PCR products were separated on
an ABI-3100 Gene Analyzer instrument, and the resultant
products were sized and genotyped by the ABI-GeneMapper
Fragment Analysis Software (version 3.5).
SNaPshot PCR reaction—Each purified PCR product
(1 μl) was added to 4 μl of a master mixture (0.5 μl SNaPshot
mix, 0.2 μl of each SNaPshot primer [10 pmol/μl], and
3.3 μl of deionized H2O) and subjected to a second PCR
reaction (35 cycles of 96 °C/10 s, 50 °C/5 s, and 60 °C/30 s).
The SNaPshot products were purified by the shrimp alkaline
phosphatase (SAP) treatment and then run on an ABI-3100
Gene Analyzer instrument. The genotyping of samples were
performed with the help of GeneMapper software (version
3.5).
Polymerase chain reaction: A set of primers was designed
(forward: 5′-AAG GCC AGC ATG GAC AAA GCT AGA-3’
and reverse: 3’-GTA GTA CAC GAA ACC CTG GTC GTA
GGT-5′) to amplify a 751 bp fragment from exon 1 of
LOXL1 that contained the two SNPs (rs1048661 [R141L] and
rs3825942 [G153D]). A second primer set was designed
(forward: 5′-TTC TTA GAA TGC AAG ACC TCA GC-3′
and reverse: 3′-CTC AGG GTA GTG GCC AGA GG-5′) to
amplify a 269 bp fragment from intron 1 that carried the
rs2165241 SNP. PCR reactions were performed to amplify a
specific fragment of genomic DNA in the MJ Research-
PTC-200 Peltier Thermal Cycler. The standard PCR program
was performed under the following conditions: 96 °C/2 min,
55 cycles (96 °C/30 s, 63 °C/30 s, and 72 °C/30 s), and 72 °C/
5 min final elongation. All the PCR products were checked
for amplification by agarose gel electrophoresis and
subsequently purified by SAP and Exo-I treatment.
DNA Sequencing: A series of oligonucleotide primers were
synthesized for amplification of seven known coding exons
of LOXL1. Each set was designed with Primer3 software and
covered at minimum 200 bp of the flanking intronic sequences
(primers are available). Exon 1 was amplified and sequenced
in two overlapping fragments. Each exon was amplified
separately; their PCR products were purified, directly
sequenced with BigDye Terminator (version 3.1) Cycle
Sequencing Kit, and run on an ABI PRISM 3100 DNA
sequencing instrument. The data were transformed to the
STADEN package, and sequences were aligned together for
each exon and for all of the 95 individuals used for this part
of our study.
Statistical analysis: The genotypic data as determined by the
SNaPshot assay were imported into an in-house SNP data
management program (SNP-STAT). The observed number of
genotypes for each SNP were counted and the genotypic and
allele frequencies were tabulated automatically. The two-
locus genotypic counts and frequencies were also estimated
for each set of SNP pairs. The standard Χ2 was used to test for
deviation from the Hardy–Weinberg equilibrium and to
compare the genotypic and allelic frequencies in exfoliation
and control groups. Odds ratios, attributable risk percents (AR
%), population attributable risk percents (PAR%), and p-
values were calculated, and their appropriate confidence
intervals were computed at the 95% level. For each sub-
phenotype (XFO, XFU, XFG, and XFS) and for each
population (American and European), this process was
repeated. The SNP-STAT program was further used to export
SNP information together with the entire genotypic data for
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use with the PLINK program [21]. All the statistical analyses
were re-evaluated by the PLINK, and in addition, this program
was used to determine the most likely haplotype-phases for
the LOXL1 SNPs and to further estimate their frequencies in
exfoliation and control groups.
RESULTS
All of 287 cases used in this study had XFS (Table 1). Subsets
had no glaucoma (XFO, n=95), glaucoma (XFG, n=133), or
remained unclassified (XFU, n=59). For each of these
phenotypic subgroups and for each of the three SNPs of the
LOXL1 gene, we tabulated both genotypic and allelic counts
separately (Table 2 and Table 3) and made a cross-comparison
statistical analysis by using a standard Χ2 test. Table 2 shows
allelic counts and corresponding uncorrected p-values for
each of the three SNPs. Of the 18 multiple tests shown in this
table, only the p-value between XFO and XFG was
significantly different. However, if one uses the Bonferroni
correction method that multiplies uncorrected p-values by the
number of comparisons performed, the reported p-value in
Table 2 becomes almost insignificant, and such marginal p-
values are always expected when a large number of statistical
comparisons are made. Table 3 presents a detailed account of
all genotypic and allelic counts and frequencies that were
observed for each of these clinical subtypes and the three
studied SNPs. Interestingly, when each of these exfoliation
subtypes was compared with the normal controls, a significant
association was detected with all the three LOXL1 SNPs.
Therefore, as no major allelic differences were observed
between these phenotypic subgroups and as each subtype is
highly associated with the three SNPs, we combined them as
a single phenotype (exfoliation syndrome, XFS) for
subsequent statistical evaluations. The observed genotypic
frequencies in Table 3 were tested for possible deviations from
the Hardy–Weinberg Equilibrium (HWE) in both the
exfoliation and control groups. No deviation was observed
from the HWE expectation for any of these two groups. As
shown in Table 3, all three SNPs are highly associated with
every single one of these clinical subtypes. For the two coding
SNPs, rs1048661 (R141L) and rs3825942 (G153D), the two
genotypes of G/G (p=2.85x10−8 and p=7.44x10−15) and the two
corresponding alleles of G (p=7.74x10−9 and p=3.10x10−17)
are highly overrepresented in the exfoliation cases (XFS) as
compared to the control group. Likewise, for the intronic SNP
of rs2165241, genotype T/T (p=1.24x10−22) and its
corresponding allele T (p=4.85x10−24) are highly associated
with XFS. Both the genotypic and allelic case-control
association tests for each of these three SNPs and for each
clinical subtype were highly significant (Table 3). We also
performed additional statistical evaluations, tabulated odds
ratios (OR), and population attributable risk percentages
(PAR%) for each of these three SNPs and under various
inherited genetic parameters (Table 4). The allelic PAR%
values for rs1048661, rs3825942, and rs2165241 were
estimated as 28%, 58%, and 32%, respectively (Table 4).
These PAR% values represent theoretical estimates for the
excessive rate of XFS in the American and European
populations that are due to risk-associated factors in LOXL1
polymorphisms. Therefore, if these specific SNP-associated
risk factors are eliminated, the incidence of XFS in the
population is expected to reduce by these percentages per each
SNP.
LOXL1 risk-associated haplotypes in exfoliation
syndrome: To determine the combined effect of these
polymorphisms on XFS, we also performed a series of
statistical analyses for all possible haplotypes of the three
SNPs. Table 5 summarizes the estimated frequencies of each
haplotype and provides results of association tests between
TABLE 2. COMPARISON OF ALLELIC COUNTS AND THE CORRESPONDING P-VALUES FOR LOXL1 SNP MARKERS OF RS1048661,RS3825942, AND
RS2165241 AND DIFFERENT SUBTYPES OF EXFOLIATION SYNDROME.
Exfoliation subtype Name of SNP Allele types Allele counts Exfoliation subtype
XFG XFU XFS
XFO (n=95) rs1048661 G/T 156/32 p1=0.517* p1=0.780 p1=0.675
rs3825942 G/A 173/15 p2=0.001 p2=0.121 p2=0.034
rs2165241 C/T 51/135 p3=0.504 p3=0.672 p3=0.823
XFG (n=133) rs1048661 G/T 225/39 - p1=0.800 p1=0.724
rs3825942 G/A 260/4 - p2=0.216 p2=0.054
rs2165241 C/T 65/199 - p3=0.301 p3=0.548
XFU (n=59) rs1048661 G/T 96/18 - - p1=0.986
rs3825942 G/A 110/4 - - p2=0.782
rs2165241 C/T 35/83 - - p3=0.494
XFS (n=287) rs1048661 G/T 477/89 - - -
rs3825942 G/A 543/23 - - -
rs2165241 C/T 151/417 - - -
* p1, p2 and p3 are the corresponding p-values for the three LOXL1 SNPs as listed for each exfoliation subtype. These are
uncorrected allelic p-values when two set of exfoliation subtypes are compared together.
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XFS and controls for each haplotype. For the first two SNPs
(rs1048661, rs3825942), haplotype GG was overrepresented
by 59% in the XFS cases (0.8021) as compared to controls
(0.5030). This deviation was statistically significant
(p=1.47x10−27). In contrast, the other two haplotypes of TG
and GA were significantly underrepresented in the XFS cases
(Table 5). The TA haplotype was not observed in the control
samples. Comparison of the two haplotypes of GG and TG
relative to GA had odds ratios of 7.87 (p=1.31x10−22) and 2.62
(p=1.51x10−4), respectively. The two haplotypes of GG and
TG accounted for 96% of the XFS cases, and the GA
haplotype had the lowest estimated risk with an attributable
risk percent (AR%) value of 394.
For the two SNPs, rs1048661 and rs2165241, all four
possible haplotypes were estimated in both cases and controls.
For this pair, only the GT haplotype was prevalent in the XFS
cases (0.7284 versus 0.4362), and this deviation (67%) from
the control group was highly significant (p=1.29x10−24). The
two haplotypes of TC (p=1.14x10−8) and GC (p=2.26x10−11)
were statistically underrepresented in the XFS cases while the
TT haplotype did not show any difference (p=0.6812)
between the two groups (Table 5). The three haplotypes of
GT, TC, and GC significantly accounted for 99% of the XFS
cases. However, when the GT, TC, and GC haplotypes were
compared relative to TT, the tabulated odds ratios of 2.01
(p=0.228), 0.629 (p=0.436), and 0.513 (p=0.261),
respectively, were not significant. The GC haplotype had the
highest AR% value of 135.
Likewise, for the last two pairs (rs3825942, rs2165241),
only the GT haplotype was overrepresented in the XFS cases
(p=2.02x10−24). The two haplotypes of GC and AC were
significantly underrepresented in the cases. Comparison of the
two common haplotypes of GT and GC relative to AC
produced odds ratios of 8.74 (p=2.51x10−23) and 3.39
(p=1.08x10−6), respectively, and these two haplotypes
accounted for 96% of XFS cases. In summary, cross
comparisons between each two pairs of SNPs revealed that
the GG, GT, and GT haplotypes were significantly
overrepresented in the XFS patients. Seven of the other eight
haplotypes were significantly more frequent in the controls.
When we tabulated the combined effect of these three
SNPs on XFS, the GGT haplotype was significantly
overrepresented (p=1.93x10−24) while the two other
haplotypes of GAC and TGC were significantly
underrepresented (Table 5). There were no significant
differences between cases and controls for the two haplotypes
of GGC and TGT. The GAT haplotype was not observed. The
combined three haplotypes of GGT, GAC, and TGC were
associated with 91% of the XFS in the study population. When
the three haplotypes of GGT, GAC, and TGC were compared
individually to non-associated haplotypes of GGC or TGT,
the estimated odds ratios of 1.38 (p=0.152) or 1.98 (p=0.240),
TABLE 3. GENOTYPIC AND ALLELIC COUNTS, FREQUENCIES, AND P-VALUES FOR THREE LOXL1 POLYMORPHISMS IN DIFFERENT SUBTYPES OF EXFOLIATION SYNDROME.
Phenotype LOXL1 SNPs rs1048661
(R141L)
rs3825942
(G153D)
rs2165241
Genotypic and allelic p-values were tabulated individually between each of the exfoliation subtypes and controls (n=333).
TABLE 4. ASSOCIATION TESTS, ODDS RATIOS, AND POPULATION ATTRIBUTABLE RISK PERCENT (PAR%) FOR THREE SNPS OF THE LOXL1 GENE.
Genetic test rs1048661
(R141L)
rs3825942
(G153D)
rs2165241
Note that p-values provided under each of these three SNPs were obtained by comparing only the rare genotypes or alleles
against other genotypes or alleles, respectively.
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GG/GT/TT G/T GG/GA/AA G/A CC/CT/TT C/T
XFO
(n=95)
Counts 62/32/0 156/32 79/15/0 173/15 4/43/46 51/135
Frequency 0.660/0.340/0.0 0.830/0.170 0.840/0.160/0.0 0.920/0.080 0.043/0.462/0.495 0.274/0.726
p-Value 1.37x10-3 5.44x10-4 9.18x10-4 1.01x10-4 5.99x10-11 2.30x10−11
XFG
(n=133)
Counts 95/35/2 225/39 128/4/0 260/4 9/47/76 65/199
Frequency 0.720/0.265/0.015 0.852/0.148 0.970/0.030/0.0 0.985/0.015 0.068/0.356/0.576 0.246/0.754
p-Value 1.49x10-5 2.53x10-6 1.21x10-11 5.59x10-13 4.83x10−17 4.17x10-17
XFU
(n=59)
Counts 40/16/1 96/18 53/4/0 110/4 3/29/27 35/83
Frequency 0.702/0.280/0.018 0.842/0.158 0.930/0.070/0.0 0.965/0.035 0.051/0.491/0.458 0.297/0.703
p-Value 8.39x10-3 2.17x10-3 1.25x10-4 1.67x10-5 8.24x10-7 3.28x10-7
XFS
(n=287)
Counts 197/83/3 477/89 260/23/0 543/23 16/119/149 151/417
Frequency 0.696/0.293/0.011 0.843/0.157 0.919/0.081/0.0 0.959/0.041 0.056/0.419/0.525 0.266/0.734
p-Value 2.85x10-8 7.74x10-9 7.44x10-15 3.10x10-17 1.24x10-22 4.85x10-24
Controls
(n=333)
Counts 162/140/28 464/196 216/98/18 530/134 94/174/60 362/294
Frequency 0.491/0.424/0.085 0.703/0.297 0.651/0.295/0.054 0.798/0.202 0.287/0.530/0.183 0.552/0.448
p-Value Odds PAR % p-Value Odds PAR % p-Value Odds PAR %
Homozygote 1.00x10-6 0.088 7 5.00x10-5 0.001 4 5.39X10-22 0.069 38
Heterozygote 3.4x10−5 0.488 14 2.46x10-12 0.195 15 1.11X10-11 0.275 34
Dominant 2.72x10-7 0.421 19 2.31x10-15 0.165 19 6.09x10-19 0.203 54
Recessive 2.89x10-5 0.116 4 7.02x10-5 0.001 3 1.38x10-13 0.149 15
Alleles 7.74x10-9 0.442 28 3.10x10-17 0.168 58 4.85x10-24 0.294 32
0.15 (p=3.31x10−10) or 4.68 (p=8.55x10−3), and 2.34
(p=5.52x10−4) or 1.63 (p=0.410), respectively, were obtained.
When the same three associated haplotypes were individually
compared to the combined haplotypes of GGC or TGT, the
estimated odds ratios of 1.44 (p=0.087), 6.42 (p=3.02x10−10),
and 2.24 (p=6.13x10−4) were obtained, respectively.
Interestingly, the lowest significant risk was associated with
the GAC haplotype (reduced by 83%), which accounted for
the greatest protection against XFS with an AR% associated
value of 457 (Table 5).
In addition to the abovementioned case-control
association studies, we also tabulated the odds ratios, AR%,
and population attributable risk percent (PAR%) for each of
these haplotypes. As presented in Table 5, risk reduction (or
risk protection for developing XFS) for highly associated
haplotypes of GA (SNPs 1 and 2), GC (SNPs 1 and 3), AC
(SNPs 2 and 3), and GAC were 394, 135, 430, and 457,
respectively. Once the combined effect of these three SNPs
was considered collectively, this data suggests that the GGT
haplotype is overrepresented by 66% in the affected patients
and therefore, is a major risk factor for XFS. On the contrary,
the GAC haplotype is underrepresented in the cases by 83%
and therefore, may play a protective role against the
development of XFS. Table 5 also provides the odds ratios
and the 95% confidence intervals for each haplotype as well
as percentages of theoretical reduction in overall incidence of
exfoliation (PAR%) if the corresponding associated haplotype
is to be eliminated (or elevated) from (or in) the population.
DNA sequencing of LOXL1 in exfoliation syndrome: To
determine the potential effect of LOXL1 mutations in XFS
patients from the population under our study, we directly
sequenced the seven coding exons of this gene in a total of 95
unselected and unrelated affected patients. The results of these
sequencings are presented in Table 6. A total of 14 DNA
variations were observed in this gene of which six were in the
coding exons and eight were in the adjacent introns. In
addition to R141L (rs1048661) and G153D (rs3825942) that
were also used in our association studies, we identified two
novel variations, G240G and V385V, each in 1 out of 95
patients. No other significant differences were observed from
the normal referenced sequence.
DISCUSSION
Recent genome-wide association studies in the Icelandic
population identified multiple SNPs from the lysyl oxidase-
like 1 (LOXL1) gene that were highly associated with XFS and
XFG [19]. The same observations were also made in the
Swedish population [19] and have further been confirmed for
two other populations [22,23]. This topic has also been
subjected to several commentaries and reviews [24-28].
We studied 620 subjects, 287 exfoliation and 333 healthy
controls from American and European populations. All
patients were genotyped using the SNaPshot Assay for three
SNPs from LOXL1 that were reported to have strong
associations with XFS in the Icelandic and Swedish
populations [19]. We also confirmed a strong association with
LOXL1 variants in our patients (Table 3–Table 5). The G
alleles of rs1048661 (SNP 1) and rs3825942 (SNP 2) together
with the T allele of rs2165241 (SNP 3) are highly associated
with XFS and XFG. When two-locus haplotypes were
tabulated between SNP 1 and SNP 2, the GG haplotype was
overrepresented in the affected cases while the TG and GA
TABLE 5. ESTIMATED TWO- AND THREE-LOCI HAPLOTYPE FREQUENCIES FOR THREE LOXL1 SNPS AND THEIR CORRESPONDING ASSOCIATION TESTS BETWEEN EXFOLIATION
SYNDROME AND CONTROLS.
SNP1 alleles SNP2 alleles XFS Controls Association tests between exfoliation and controls
rs1048661 rs3825942 n=566 n=658 p-Values Odds (95% C.I.) AR% PAR%
G G 0.8021 0.503 1.47x10−27 4.00 (3.10–5.18) 37 22
T G 0.1572 0.2964 9.01x10−9 0.44 (0.33–0.59) 88 28
G A 0.0406 0.2006 4.83x10−17 0.17 (0.11–0.27) 394 58
rs1048661 rs2165241 n=560 n=650 p-Values Odds (95% C.I.) AR% PAR%
G T 0.7284 0.4362 1.29x10−24 3.46 (2.71–4.41) 40 24
T C 0.1499 0.287 1.14x10−8 0.44 (0.33–0.58) 91 28
G C 0.1126 0.2653 2.26x10−11 0.35 (0.26–0.48) 135 36
T T 0.0091 0.0115 0.6812 0.83 (0.26–2.62) 21 9
rs3825942 rs2165241 n=560 n=654 p-Values Odds (95% C.I.) AR% PAR%
G T 0.7364 0.4458 2.02x10−24 3.45 (2.71–4.40) 39 23
G C 0.2266 0.3547 1.16x10−6 0.53 (0.41–0.69) 56 20
A C 0.037 0.1995 1.49x10−17 0.16 (0.10–0.25) 430 60
Combined haplotypes* n=566 n=666 p-Values Odds (95% C.I.) AR% PAR%
GGT 0.7278 0.4382 1.93x10−24 3.43 (2.69–4.36) 40 23
GAC 0.0346 0.1973 4.99x10−18 0.15 (0.09–0.24) 457 60
TGC 0.1486 0.2877 5.82x10−9 0.43 (0.32–0.57) 94 29
GGC 0.0795 0.0661 0.3693 1.22 (0.79–1.88) 17 9
TGT 0.0097 0.0107 0.8595 0.84 (0.26–2.66) 19 8
Individual p-values for each haplotype, odds ratios, 95% confidence intervals, their associated attributable risks percentages
(AR%), and population attributable risks percentages (PAR%) between exfoliation syndrome and controls are provided. * Order
of the alleles are: rs1048661, rs3825942, and rs2165241.
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haplotypes were significantly underrepresented in the cases.
Comparison of the two haplotypes of GG and TG relative to
GA had odds ratios of 7.87 (p=1.31x10−22) and 2.62
(p=1.51x10−4), respectively. The two haplotypes of GG and
TG accounted for 96% of the XFS cases, and this observation
is in full agreement with the original report for the Icelandic
and Swedish populations [19]. Similarly, for each two-set of
SNP, the GG, GT, and GT haplotypes were significantly
overrepresented in the XFS patients. Seven of the other eight
haplotypes were significantly more frequent in the control
patients. When the combined effects of these three SNPs were
tabulated, the GGT haplotype was significantly
overrepresented while the two haplotypes of GAC and TGC
were significantly underrepresented in the XFS patients
(Table 5). These three haplotypes accounted for 91% of the
XFS cases in the studied population. In summary, for these
three SNPs, the GGT haplotype was overrepresented by 66%
and constituted a major risk haplotype for XFS while the GAC
haplotype was underrepresented by 83% and had the lowest
associated risk in XFS patients. DNA sequencing of 95
affected patients did not show any mutations in LOXL1 in our
studied population.
LOXL1 belongs to a family of extracellular copper-
requiring enzymes (i.e., LOX, LOXL1–4) that facilitate cross-
linking of collagens and elastins through oxidative
deamination of lysine or hydroxylysine side chains [29]. The
reported LOXL1 risk-associated polymorphisms in XFS [19]
may be a significant finding as this condition is considered to
be a type of elastosis that affect elastic microfibrils. However,
as the most highly XFS-associated haplotypes were also
present in 44%–50% of our control subjects (Table 5), it is not
clear at this point how these naturally occurring variations
work individually or cooperatively to contribute to this
phenotype. Since LOXL1 interacts with other proteins [30,
31] such as fibulin-5 (FBLN5) and elastin (ELN), it is likely
that through these protein–protein interactions and their
anticipated common biochemical pathways, the effect of such
polymorphisms on XFS becomes more significant. The two
highly associated SNPs of rs1048661 (R141L; basic arginine
replaced by neutral and hydrophobic leucine) and rs3825942
(G153D; neutral and polar glycine replace by acidic aspartic
acid) are part of the coding region of the LOXL1 protein, and
these two amino acids are highly conserved during evolution.
There is also a strong linkage disequilibrium between these
two SNPs (D’=0.996) thus suggesting that the effect of these
two amino acid polymorphisms on XFS is probably
influenced by protein–protein interaction of LOXL1 with
FBLN5, ELN, or other, unidentified LOXL1-interacting
proteins. Identification of specific polymorphisms in LOXL1
that are highly associated with XFS and XFG provide a good
starting point for future research into the etiology of this
condition. Although LOXL1 null mice [32] have not been
specifically reported to have any ocular phenotype resembling
XFS, perhaps the study of such animals at very old stages of
life and/or their cross-breeding with other animals lacking
LOXL1-interacting proteins such as FBLN5 and ELN are now
warranted. However, as LOXL1 polymorphisms are
frequently seen in normal patients, it is not clear at this point
how such information can provide any immediate assistance
to patients having this condition or being at high risk for
development of XFS or XFG.
It is now possible to determine specific haplotype
composition of LOXL1 polymorphisms in an individual
patient and use the anticipated population-related risk
frequencies to categorize a person into a relatively high or low
risk group. However, it is not clear at this point if such
information should be used to alter the normal clinical
management of an individual as these risk estimates are
relative, tentative, conditional, and probably population
specific. More importantly, such polymorphisms are also
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TABLE 6. DNA SEQUENCING RESULTS OF 95 PATIENTS WITH EXFOLIATION SYNDROME.
Location Nucleotide change Amino acid
change
SNP number Wildtype homozygous Number of subjects observed with this variant
Heterozygous Homozygous
Exon 1 CGG>CTG R141L rs1048661 61 33 1
GGC>GAC G153D rs3825942 90 5 0
GGC>GGT G240G - 94 1 0
GAC>GAT D292D - 93 2 0
GCG>GCT A320A - 82 12 1
Exon 2 GTG>GTC V385V - 94 1 0
Intron 2 IVS2+197C>T - rs2304719 84 11 0
Intron 3 IVS3+23C>T - - 94 1 0
IVS3–155G>A - - 82 13 0
IVS3–101G>A - - 66 28 0
Intron 4 IVS4+49G>A - - 94 1 0
Intron 5 IVS5+111C>A - rs2304721 79 15 1
IVS5–121C>T - - 88 6 0
IVS5–51T>C - rs2304722 67 28 0
A total of 14 DNA variations were observed in this gene of which six were in the coding exons and eight were in the adjacent
introns.
significantly observed in healthy control subjects. Therefore,
it is unlikely that such information will be useful for
immediate day-to-day clinical management of patients.
It is also interesting that LOXL1 polymorphisms are
highly associated with both XFS and XFG, but no such
association was reported for subjects only affected with
primary open-angle glaucoma [19]. This in turn suggests that
other factors must exist that predisposes an individual to
develop glaucoma. Therefore, it is likely that XFG represents
a group of patients that were hereditarily predisposed to
glaucoma, but they instead developed XFG either because of
LOXL1 associated polymorphisms impacting the predisposed
glaucoma gene expression and protein function or because of
other as yet unknown systemic, hereditary, or environmental
factors. Further research into the role of the LOXL1 protein
in the etiology of exfoliation syndrome and exfoliation
glaucoma is urgently needed.
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